Abstract

STABILITY INDICATING RP-HPLC METHOD DEVELOPMENT AND VALIDATION FOR SIMULTANEOUS ESTIMATION OF AZILSARTAN AND CHLORTHALIDONE IN BULK AND PHARMACEUTICAL DOSAGE FORM

Vamsi Gopi Krishna Kodirekka* and Dr. S. Shobha Rani

ABSTRACT

Azilsartan and Chlorthalidone are used to treat hypertension treatment. For evolving and simultaneous estimation of Azilsartan and chlorthalidone in API and Pharmaceutical dosage form a trouble-free, true, clear-cut tactics was evolveed. Std Zorbax 150 x 4.6 mm, 5m was used to run the chromatogram. Includes a mobile phase 0.1 % OPA buffer: Methanol was pumped through the column at a rate of 1.0 ml/min in a 60:40 ratio. This tactics used 0.1 % OPA buffer as a buffer. The temperature was kept at 30°C. 240.0 nm was chosen as the optimal wavelength. Azilsartan and Chlorthalidone had retention times of 2.402 and 3.323 minutes, respectively. Azilsartan's and Chlorthalidone's RSDs were determined to be 0.9 percent and 0.5 percent, respectively. For Azilsartan and Chlorthalidone, the recovery rates were 101.64 percent and 99.96 percent, respectively. The LOD, LOQ values derived from Azilsartan and Chlorthalidone regression models were 0.13, 0.41, and 0.01, 0.03 respectively. AZT's regression equation is y = 35736x + 14566, whereas CHD's is y = 20467x + 3190. Although retention times and run times were minimized, the tactics evolveed was easy and cost-effective, and it could be used in routine quality control tests in industries.

Keywords: .